Drugs / LBL-034
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06049290 | Oct 2023 → Oct 2026 expected | refractory plasma cell neoplasm | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBL-034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06049290 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06049290 ↗ |